Please login to the form below

Not currently logged in
Email:
Password:

GSK strikes deal with Dr. Reddy's

GSK has entered into an agreement with Dr. Reddy's Laboratories to develop and market selected products across an extensive number of emerging markets, excluding India

GlaxoSmithKline (GSK) has entered into an agreement with Dr. Reddy's Laboratories to develop and market selected products across an extensive number of emerging markets, excluding India.

Under the agreement, GSK will gain exclusive access to Dr. Reddy's portfolio and future pipeline of more than 100 branded pharmaceuticals in fast growing therapeutic segments such as cardiovascular, diabetes, oncology, gastroenterology and pain management.

The products will be manufactured by Dr. Reddy's and licensed and supplied by GSK in various countries in Africa, the Middle East, Asia Pacific and Latin America.

In certain markets, products will be co-marketed by GSK and Dr. Reddy's. Under the terms of the agreement, revenues will be reported by GSK and shared with Dr. Reddy's as per the agreed terms.

According to GV Prasad, vice chairman and CEO, Dr. Reddy's: "We hope to take our purpose of providing affordable and innovative medicines to a much wider population through this partnership."

Abbas Hussain, president for emerging markets at GSK said: "This is another significant step forward in our strategy to grow and diversify GSK's business in emerging markets."

15th June 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics